Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Zelira Therapeutics stock

ZLD.AX
AU000000ZLD1
A2AS5H

Price

0.63
Today +/-
+0
Today %
+0 %

Zelira Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Zelira Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Zelira Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Zelira Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Zelira Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Zelira Therapeutics Stock Price History

DateZelira Therapeutics Price
1/17/20250.63 undefined
1/16/20250.63 undefined
1/15/20250.63 undefined
1/14/20250.62 undefined
1/13/20250.65 undefined
1/10/20250.63 undefined
1/9/20250.63 undefined
1/8/20250.63 undefined
1/7/20250.63 undefined
1/6/20250.65 undefined
1/3/20250.63 undefined
1/2/20250.62 undefined
12/31/20240.62 undefined
12/30/20240.63 undefined
12/27/20240.62 undefined
12/24/20240.57 undefined
12/23/20240.62 undefined

Zelira Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Zelira Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Zelira Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Zelira Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Zelira Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Zelira Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Zelira Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Zelira Therapeutics’s growth potential.

Zelira Therapeutics Revenue, EBIT and net profit per share

DateZelira Therapeutics RevenueZelira Therapeutics EBITZelira Therapeutics Net Income
2026e24.9 B undefined-2.83 M undefined-5.06 M undefined
2025e46.54 M undefined19 M undefined11,463.5 undefined
202495,260 undefined-5.01 M undefined-36.57 M undefined
2023551,260 undefined-5.87 M undefined-5.57 M undefined
20222.89 M undefined-11.7 M undefined-11.95 M undefined
20212.09 M undefined-7.86 M undefined-8.55 M undefined
20201.04 M undefined-6.9 M undefined-7.02 M undefined
2019859,170 undefined-3.38 M undefined-3.57 M undefined
2018561,390 undefined-2.27 M undefined-1.73 M undefined
2017167,760 undefined-2.44 M undefined-6.16 M undefined
20162,730 undefined-397,580 undefined-898,640 undefined
201511,590 undefined-412,240 undefined-400,080 undefined
201420,000 undefined-270,000 undefined-290,000 undefined
201330,000 undefined-290,000 undefined-310,000 undefined
201230,000 undefined-600,000 undefined-640,000 undefined
2011500,000 undefined40,000 undefined10,000 undefined
2010160,000 undefined-1 M undefined-1.69 M undefined
2009130,000 undefined-1 M undefined-20.27 M undefined
200820,000 undefined-270,000 undefined12.61 M undefined
200721.15 M undefined-17.36 M undefined-38.16 M undefined
2006240,000 undefined-3.98 M undefined-900,000 undefined
2005730,000 undefined-300,000 undefined-310,000 undefined

Zelira Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e
00000.02000000000000000000.0524.9
------------------100.00----54,030.43
-100.00--23.81------------100.0050.0050.00--2.170.00
000050000000000000110000
0000-3812-20-1000000-6-1-3-7-8-11-5-360-5
------131.58-266.67-95.00--------83.33200.00133.3314.2937.50-54.55620.00--
0.130.991.071.452.164.7530.4458.7858.7856.0896.4796.4796.470.652.834.314.314.846.698.0410.0711.3500
------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Zelira Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Zelira Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (k)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (k)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (k)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                           
0.92.151.461.960.231.092.710.340.791.280.970.60.320.067.875.693.071.74.972.750.150.59
0000400060070008.5631.8399.391.0951.46042.1101.43-8.6512.99
00001.070.0300.030.02000000000.060.010.1502.13
00.250.250.374.2600000000000000.871.961.531.25
0.1005.383.6800.6200000000000.070.20.120.10.27
12.41.717.719.281.123.330.430.811.350.970.60.330.097.975.783.121.836.095.081.774.26
0.24.987.1817.8100.270.10.070.070.080.110.180.080000.031.581.240.850.520.23
00000002000000000537357.6350.35166.964.1143.4343.46
01.061.060.02000000000000000.020.160.010
000000000000000001.281.120.970.810.65
0000000000000000030.7530.7530.7530.750
00000000000000000010064430
0.26.048.2417.8300.270.10.270.070.080.110.180.08000.540.3933.9633.3932.8432.170.92
1.28.449.9525.549.281.393.430.70.881.431.080.780.410.097.976.313.5235.7939.4837.9233.945.18
                                           
0.658.410.314.4324.8228.3314.9514.9514.9515.9615.9615.9615.9716.3113.813.8213.8226.0836.6543.7545.5245.52
0000000000000000000000
-0.09-0.11-0.420.45-39.66-27.05-12.47-14.29-14.29-14.61-14.92-15.21-15.61-16.51-5.91-7.61-10.728.581.34-8.06-13.14-49.92
00000000000000000-0.11-0.16-0.48-0.57-0.11
0000000000000000000000
0.568.299.8814.88-14.841.282.480.660.661.351.040.750.36-0.27.96.213.1134.5537.8335.231.8-4.51
0.10.060.062.6918.890.110.270.040.220.080.040.030.050.290.070.10.410.560.981.511.743.41
0000000000000000000000
0.590.20.092.491.910.01000000000000.050000
0002.853.3200000000000000003.54
0000000000000000060.8690.53116.71142.53146.06
0.690.260.158.0324.120.120.270.040.220.080.040.030.050.290.070.10.410.671.081.631.887.09
0000.16000.800000000000.570.460.380.32.26
000130000000000000000000
0003.26000000000000000-0.490.090
0003.55000.800000000000.570.46-0.10.392.26
0.690.260.1511.5824.120.121.070.040.220.080.040.030.050.290.070.10.411.241.541.522.279.36
1.258.5510.0326.469.281.43.550.70.881.431.080.780.410.097.976.313.5235.7939.3736.7334.074.84
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Zelira Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Zelira Therapeutics's financial health and stability.

Assets

Zelira Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Zelira Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Zelira Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Zelira Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200320042005200620072008200920102011201220132014201520162017201820192020202120222023
000000000000000000-8-11-5
000000000000000000000
000000000000000000000
0-1-1-6-4-2000000000-1-2-3-1-10
00000000000000000002-3
000000000000000000000
000000000000000000000
0-2-2-7-14-2-1-1000000-2-2-3-6-8-9-7
0-10000000000000000000
0-10000000000000001102
000000000000000001102
000000000000000000000
000220100000000000000
162410320010000100041071
15171333001000090041071
---------------------
000000000000000000000
00-10-1200-30000005-3-3-4-3-10-9
-0.21-3.81-2.64-7.42-15.05-2.21-1.65-1.310.09-0.59-0.29-0.36-0.29-0.33-2.21-2.62-3.37-6.95-8.62-9.43-7.25
000000000000000000000

Zelira Therapeutics stock margins

The Zelira Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Zelira Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Zelira Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Zelira Therapeutics's sales revenue. A higher gross margin percentage indicates that the Zelira Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Zelira Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Zelira Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Zelira Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Zelira Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Zelira Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Zelira Therapeutics Margin History

Zelira Therapeutics Gross marginZelira Therapeutics Profit marginZelira Therapeutics EBIT marginZelira Therapeutics Profit margin
2026e11.12 %-0.01 %-0.02 %
2025e11.12 %40.83 %0.02 %
202411.12 %-5,258.43 %-38,388.52 %
202334.23 %-1,064.87 %-1,010.96 %
202267.55 %-404.5 %-412.84 %
202189.09 %-375.51 %-408.58 %
202011.12 %-662.87 %-674.28 %
201911.12 %-393.31 %-415.26 %
201811.12 %-403.79 %-308.13 %
201711.12 %-1,453.54 %-3,670.37 %
201611.12 %-14,563.37 %-32,917.22 %
201511.12 %-3,556.86 %-3,451.94 %
201411.12 %-1,350 %-1,450 %
201311.12 %-966.67 %-1,033.33 %
201211.12 %-2,000 %-2,133.33 %
201111.12 %8 %2 %
201011.12 %-625 %-1,056.25 %
200911.12 %-769.23 %-15,592.31 %
2008100 %-1,350 %63,050 %
200727.28 %-82.08 %-180.43 %
2006100 %-1,658.33 %-375 %
200511.12 %-41.1 %-42.47 %

Zelira Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Zelira Therapeutics earnings per share therefore indicates how much revenue Zelira Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Zelira Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Zelira Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Zelira Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Zelira Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Zelira Therapeutics Revenue, EBIT and net profit per share

DateZelira Therapeutics Sales per ShareZelira Therapeutics EBIT per shareZelira Therapeutics Earnings per Share
2026e2,193.92 undefined0 undefined-0.45 undefined
2025e4.1 undefined0 undefined0 undefined
20240.01 undefined-0.44 undefined-3.22 undefined
20230.05 undefined-0.58 undefined-0.55 undefined
20220.36 undefined-1.46 undefined-1.49 undefined
20210.31 undefined-1.17 undefined-1.28 undefined
20200.21 undefined-1.42 undefined-1.45 undefined
20190.2 undefined-0.78 undefined-0.83 undefined
20180.13 undefined-0.53 undefined-0.4 undefined
20170.06 undefined-0.86 undefined-2.18 undefined
20160 undefined-0.62 undefined-1.39 undefined
20150 undefined-0 undefined-0 undefined
20140 undefined-0 undefined-0 undefined
20130 undefined-0 undefined-0 undefined
20120 undefined-0.01 undefined-0.01 undefined
20110.01 undefined0 undefined0 undefined
20100 undefined-0.02 undefined-0.03 undefined
20090 undefined-0.03 undefined-0.67 undefined
20080 undefined-0.06 undefined2.65 undefined
20079.79 undefined-8.04 undefined-17.67 undefined
20060.17 undefined-2.74 undefined-0.62 undefined
20050.68 undefined-0.28 undefined-0.29 undefined

Zelira Therapeutics business model

Zelira Therapeutics was founded in 2016 with its headquarters in Perth, Australia. The company focuses on the development, production, and marketing of medical cannabis to meet the needs of patients worldwide. The company's business model is based on producing medical cannabis specifically tailored to patients' needs. It works closely with doctors and patients to ensure its products are effective and meet patients' needs. Zelira Therapeutics operates in three main areas. The first is the development of products for treating pain and inflammation in chronic conditions such as multiple sclerosis, cancer, and epilepsy. The second area includes the development of products for treating sleep disorders. The third area is the development of products for treating mental disorders such as anxiety and depression. The company has developed a wide range of products, including oils, pills, sprays, and topical creams. An example of a product is the ZTL-101 oil, which was developed for treating pain and inflammation in patients with osteoarthritis. The oil contains a combination of CBD and THC. The company has also partnered with the University of Mississippi to research the use of medical cannabis for treating post-traumatic stress disorder (PTSD). The research is funded by the US government and aims to legitimize the use of medical cannabis for treating PTSD. Zelira Therapeutics has also formed partnerships with other companies and organizations to advance its research and development. In 2020, the company entered into an agreement with Emerald Health Therapeutics, a Canadian company specializing in the production of medical cannabis. The two companies will collaborate on developing products for treating sleep disorders. The company has also partnered with iCAN Israel-Cannabis, an Israel-based company specializing in the research and development of medical cannabis. The two companies are working together to develop new products and promote the use of medical cannabis in various countries. In addition to its partnerships, Zelira Therapeutics has established a strong presence in various international markets. It is currently operating in the US, Australia, New Zealand, and Germany, and is working to expand into other countries. Overall, Zelira Therapeutics is a company specializing in the development of medical cannabis for treating various conditions. It has a wide range of products and works closely with doctors and patients to ensure their effectiveness and meet patients' needs. With strong partnerships and a presence in various international markets, the company has a promising future. Zelira Therapeutics is one of the most popular companies on Eulerpool.com.

Zelira Therapeutics SWOT Analysis

Strengths

Zelira Therapeutics Ltd has an experienced team of professionals who possess in-depth knowledge of the pharmaceutical and biotechnology industries.

The company has a strong portfolio of proprietary products and intellectual property focused on medical cannabis and cannabinoid-based therapies.

Zelira Therapeutics has established partnerships with renowned research institutions, enabling ongoing development and innovation in the field of cannabis-based medicine.

The company has a strong financial position with steady revenue growth, allowing for investments in research and development, as well as marketing and distribution efforts.

Weaknesses

Being a relatively small company, Zelira Therapeutics Ltd may face challenges in competing with larger pharmaceutical and biotech companies that have greater resources and market presence.

The regulatory environment for medical cannabis and cannabinoid-based therapies can be complex and subject to change, potentially affecting Zelira Therapeutics' ability to bring products to market.

As a company focused on cannabis-based medicine, Zelira Therapeutics may face skepticism or stigmatization from certain segments of the medical community and general public.

Opportunities

The increasing acceptance and legalization of medical cannabis in various jurisdictions provide Zelira Therapeutics with an opportunity to expand its market presence and reach new customers.

Emerging research and clinical trials showcasing the potential benefits of medical cannabis and cannabinoid-based therapies can open new doors for Zelira Therapeutics in terms of product development and commercialization.

Collaborations with pharmaceutical companies and healthcare providers can help Zelira Therapeutics in accessing larger distribution networks and tapping into established customer bases.

Threats

The competitive landscape of the medical cannabis and cannabinoid-based therapeutics industry is rapidly evolving, and Zelira Therapeutics may face increased competition from new entrants or established players.

Changes in regulatory policies and legal restrictions related to medical cannabis can impact Zelira Therapeutics' ability to operate and distribute their products in certain markets.

Market volatility and fluctuating consumer demand for medical cannabis and cannabinoid-based therapies may pose challenges to Zelira Therapeutics' revenue stability and growth.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Zelira Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Zelira Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Zelira Therapeutics shares outstanding

The number of shares was Zelira Therapeutics in 2024 — This indicates how many shares 11.347 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Zelira Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Zelira Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Zelira Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Zelira Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Zelira Therapeutics stock splits

In Zelira Therapeutics's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Zelira Therapeutics.

Zelira Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
12/31/2021-0.35 -0.88  (-147.52 %)2022 Q2
12/31/2020-0.35 -0.53  (-48.51 %)2021 Q2
6/30/20200 -0.88  (0 %)2020 Q4
1

Zelira Therapeutics shareholders

%
Name
Stocks
Change
Date
9.99686 % Majeed (Malik)1,134,64408/21/2024
4.02310 % Quincy Street Capital LLC456,62208/21/2024
3.77870 % Imasogie (Osagie O)428,88306/30/2024
3.46404 % Rochlin (Sharri J)393,16808/21/2024
3.46404 % Kerekes (Zoltan)393,16808/21/2024
3.38084 % Sunset Capital Management Pty. Ltd.383,72508/21/2024
3.36553 % Gray (Lisa)381,98808/21/2024
2.92933 % Mera 1 LLC332,47908/21/2024
2.75001 % Muller CT Pty. Ltd.312,126312,1268/21/2024
2.70885 % Geers (Torsten M)307,45408/21/2024
1
2

Zelira Therapeutics Executives and Management Board

Dr. Oludare Odumosu

Zelira Therapeutics Global Chief Executive Officer and Managing Director (since 2019)
Compensation 642,049

Mr. Osagie Imasogie

(61)
Zelira Therapeutics Chairman of the Board (since 2019)
Compensation 528,593

Mr. Timothy Slate

Zelira Therapeutics Company Secretary, Non-Executive Director (since 2016)
Compensation 15,000

Mr. Greg Blake

Zelira Therapeutics Executive Director (since 2023)

Dr. Donna O'Donnell

Zelira Therapeutics Non-Executive Director
1
2

Most common questions regarding Zelira Therapeutics

What values and corporate philosophy does Zelira Therapeutics represent?

Zelira Therapeutics Ltd is a renowned company that holds strong values and corporate philosophy. Committed to excellence, Zelira strives to deliver innovative and effective therapeutic solutions. Their dedication lies in improving the quality of life for patients through the development of clinically validated cannabis-based medicines. With a focus on research and development, Zelira aims to provide evidence-based treatments to address unmet medical needs. Their core principles revolve around integrity, collaboration, and patient-centricity. By maintaining ethical standards and fostering partnerships, Zelira Therapeutics Ltd empowers patients and healthcare practitioners alike, driving advancements in the field of medicinal cannabis.

In which countries and regions is Zelira Therapeutics primarily present?

Zelira Therapeutics Ltd is primarily present in Australia and the United States.

What significant milestones has the company Zelira Therapeutics achieved?

Zelira Therapeutics Ltd, a renowned biopharmaceutical company, has achieved several significant milestones. The company has successfully developed and commercialized innovative therapeutic solutions for various medical conditions. Zelira Therapeutics has witnessed notable milestones, including the establishment of strategic partnerships with leading research institutions and pharmaceutical companies. Additionally, they have obtained regulatory approvals for their groundbreaking pharmaceutical products, enhancing patient access to cutting-edge treatments. Zelira Therapeutics Ltd has demonstrated consistent dedication to pioneering research, driving innovation, and improving patient outcomes. With their unwavering commitment to scientific excellence, Zelira Therapeutics continues to redefine possibilities in the pharmaceutical industry.

What is the history and background of the company Zelira Therapeutics?

Zelira Therapeutics Ltd is a renowned global therapeutic medicinal cannabis company. Founded in 2016, the company focuses on the development and commercialization of innovative pharmaceutical-grade cannabinoid-based therapies. With a mission to improve patients' quality of life, Zelira Therapeutics conducts extensive research to develop evidence-based medicinal cannabis treatments targeting a range of medical conditions. The company collaborates with leading researchers, clinicians, and health organizations to ensure the highest standards in product development. Zelira Therapeutics aims to bring effective and safe cannabis-based therapies to patients worldwide.

Who are the main competitors of Zelira Therapeutics in the market?

Zelira Therapeutics Ltd faces competition from various players in the market. Some of the main competitors of Zelira Therapeutics Ltd include prominent pharmaceutical companies such as GW Pharmaceuticals, Canopy Growth Corporation, and Aphria Inc. These companies also operate in the medical cannabis industry and offer a range of products and services similar to Zelira Therapeutics Ltd. Competition in the market drives innovation and fosters growth, allowing customers to choose from diverse options. Zelira Therapeutics Ltd continues to engage in strategic initiatives to differentiate itself and stay competitive in this dynamic market.

In which industries is Zelira Therapeutics primarily active?

Zelira Therapeutics Ltd is primarily active in the pharmaceutical and healthcare industries.

What is the business model of Zelira Therapeutics?

The business model of Zelira Therapeutics Ltd revolves around developing and commercializing evidence-based pharmaceutical-grade cannabis products for the treatment of various medical conditions. As a leading global medicinal cannabis company, Zelira Therapeutics focuses on research, development, clinical trials, and partnerships to bring innovative therapeutic solutions to patients. With a patient-centered approach, Zelira Therapeutics aims to improve patients' quality of life by providing safe and effective alternative treatments. Through strategic partnerships and collaborations, the company ensures its products reach a wider market, expanding its global footprint in the rapidly evolving medicinal cannabis industry.

What is the P/E ratio of Zelira Therapeutics 2025?

The Zelira Therapeutics P/E ratio is 623.61.

What is the P/S ratio of Zelira Therapeutics 2025?

The Zelira Therapeutics P/S ratio is 0.15.

What is the Quality Investing of Zelira Therapeutics?

The Quality Investing for Zelira Therapeutics is 7/10.

What is the revenue of Zelira Therapeutics 2025?

The expected Zelira Therapeutics revenue is 46.54 M AUD.

How high is the profit of Zelira Therapeutics 2025?

The expected Zelira Therapeutics profit is 11,463.5 AUD.

What is the business model of Zelira Therapeutics

Zelira Therapeutics Ltd is a global company in the pharmaceutical development and sales of medical marijuana products. The company was founded to enhance the development and sales of therapeutic and medical marijuana products. Zelira Therapeutics aims to serve its customers through innovative, effective, and safe products of exceptional quality and efficiency. The business model of Zelira Therapeutics is focused on being a leader in the medical marijuana industry. The company concentrates on innovative products tailored to the needs of patients and doctors. Zelira Therapeutics possesses extensive knowledge and collaboration with renowned companies to develop the latest and most advanced technologies and products. The company has various divisions that focus on the development of medical marijuana products. One of them is the research and development of products tailored to various therapeutic applications such as the treatment of chronic pain, sleep disorders, and inflammation. Zelira Therapeutics has also developed innovative products targeting patients with epilepsy and autism. Another focus of Zelira Therapeutics is the sale of medical marijuana. The company has partnerships with organizations specialized in the manufacturing and sale of medical marijuana. Zelira Therapeutics strives to serve its customers through effective and safe delivery of marijuana products. The company offers various products, including oral sprays, capsules, and topical creams. A popular product of Zelira Therapeutics is the oral spray, which provides a quick and effective method of administering marijuana. The company has also developed a range of topical creams that can be used for pain relief and inflammation. Capsules provide an excellent way to precisely control dosage. Zelira Therapeutics also has a department for international business activities. Here, the company focuses on collaborations with international partners to distribute its products worldwide. The International Business Development department has enabled the company to sell its products in various countries such as Australia, Germany, and Canada. Zelira Therapeutics also has plans to expand into new markets like the United Kingdom and Spain. Overall, Zelira Therapeutics offers differentiated products based on the needs of patients and therapy methods. The company strives to provide its customers with safe, effective, and high-quality marijuana products. With a strong focus on research and development and unique partnerships, Zelira Therapeutics is well-equipped to continue playing a leading role in the medical marijuana industry.

What is the Zelira Therapeutics dividend?

Zelira Therapeutics pays a dividend of 0 AUD distributed over payouts per year.

How often does Zelira Therapeutics pay dividends?

The dividend cannot currently be calculated for Zelira Therapeutics or the company does not pay out a dividend.

What is the Zelira Therapeutics ISIN?

The ISIN of Zelira Therapeutics is AU000000ZLD1.

What is the Zelira Therapeutics WKN?

The WKN of Zelira Therapeutics is A2AS5H.

What is the Zelira Therapeutics ticker?

The ticker of Zelira Therapeutics is ZLD.AX.

How much dividend does Zelira Therapeutics pay?

Over the past 12 months, Zelira Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Zelira Therapeutics is expected to pay a dividend of 0 AUD.

What is the dividend yield of Zelira Therapeutics?

The current dividend yield of Zelira Therapeutics is .

When does Zelira Therapeutics pay dividends?

Zelira Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Zelira Therapeutics?

Zelira Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Zelira Therapeutics?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Zelira Therapeutics located?

Zelira Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Zelira Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Zelira Therapeutics from 1/20/2025 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 1/20/2025.

When did Zelira Therapeutics pay the last dividend?

The last dividend was paid out on 1/20/2025.

What was the dividend of Zelira Therapeutics in the year 2024?

In the year 2024, Zelira Therapeutics distributed 0 AUD as dividends.

In which currency does Zelira Therapeutics pay out the dividend?

The dividends of Zelira Therapeutics are distributed in AUD.

All fundamentals about Zelira Therapeutics

Our stock analysis for Zelira Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Zelira Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.